Lineage Cell Therapeutics Withdraws CIRM Grant Application and Plans Resubmission
I'm PortAI, I can summarize articles.
Lineage Cell Therapeutics Inc. has withdrawn its application for a Clinical Trial award from the California Institute for Regenerative Medicine (CIRM) to support the development of OPC1 for spinal cord injuries. The company plans to address feedback and resubmit in January 2026. This does not affect ongoing or planned development of OPC1 or the DOSED clinical study.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments